Intellia upgraded to Outperform from Market Perform at Citizens JMP

Citizens JMP analyst Silvan Tuerkcan upgraded Intellia Therapeutics (NTLA) to Outperform from Market Perform with a $33 price target The firm’s survey of North American allergist-immunologists highlights “strong interest in a once-and-done prophylactic therapy.” The results indicate an over 19% market share for Intellia’s NTLA-2002, or a $2.8B opportunity, the analyst tells investors in a research note. Citizens has confidence in the company’s Phase 3 data expected in the first half of 2026 and application submission timeline. It sees an attractive valuation and positive outlook for Intellia at current share levels.